Methods of administering antibodies that bind interleukin 13
The method of subcutaneous administration of anti-IL-13 antibodies with tailored dosing schedules addresses the high injection burden of current treatments, offering effective atopic dermatitis management with reduced frequency.
TW202629604APending Publication Date: 2026-07-16APOGEE THERAPEUTICS INC
0 Cites 0 Cited by
Patent Information
- Application Number
- TW114139350
- Authority / Receiving Office
- TW · TW
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2025-09-12
- Filing Date
- 2025-10-13
- Publication Date
- 2026-07-16
AI Technical Summary
Technical Problem
Current treatments for atopic dermatitis require frequent injections of monoclonal antibodies, which impose a high injection burden on patients with this chronic disease.
Method used
A treatment method involving subcutaneous administration of anti-IL-13 antibodies or its antigen-binding fragments with specific amino acid sequences, utilizing induction and maintenance doses at varying intervals to reduce the frequency of injections.
Benefits of technology
The method provides effective treatment for atopic dermatitis with a lower administration frequency, improving patient compliance and reducing the burden of frequent injections.
✦ Generated by Eureka AI based on patent content.
Abstract
Described herein are methods of administration of antibodies that bind interleukin 13 (IL-13) and methods of use thereof. In certain aspects, described herein are methods of inhibiting IL-13 biological activity. In certain aspects, the antibodies and methods described herein are used for treatment of an inflammatory disorder or disease, such as atopic dermatitis.
Need to check novelty before this filing date? Find Prior Art